ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Scilex Holding Company

Scilex Holding Company (SCLX)

0,5045
0,00
(0,00%)
Fermé 18 Décembre 10:00PM
0,5092
0,0047
(0,93%)
Après les heures de négociation: 1:05AM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
0,5092
Prix Achat
0,50
Prix Vente
0,5148
Volume échangé
703 944
0,49 Fourchette du Jour 0,5399
0,4559 Plage de 52 semaines 2,63
Cap du marché
Clôture Veille
0,5045
Ouverture
0,51
Dernière Transaction
3
@
0.5
Dernière heure de transaction
Volume financier
US$ 357 884
VWAP
0,508399
Volume moyen (3 m)
2 177 307
Actions en circulation
191 790 520
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,84
Bénéfice par action (BPA)
-0,6
Chiffre d'affairess
46,74M
Bénéfice net
-114,33M

À propos de Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the ... Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Siège social
Wilmington, Delaware, USA
Fondé
-
Scilex Holding Company est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker SCLX. Le dernier cours de clôture d'Scilex était de US$0,50. Au cours de la dernière année, les actions de Scilex ont été négociées dans une fourchette de prix de US$ 0,4559 à US$ 2,63.

Scilex compte actuellement 191 790 520 actions en circulation. La capitalisation boursière d'Scilex est de US$96,76 million. Scilex a un ratio cours/bénéfice (ratio PE) de -0.84.

SCLX Dernières nouvelles

Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

PALO ALTO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing...

Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering

PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing...

Scilex Holding Company Announces $17 Million Registered Direct Offering

PALO ALTO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing...

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Currently enrolling randomized, double-blind, placebo-controlled, dose-finding, Phase 2 clinical trial to evaluate the safety and efficacy of KDS2010 in patients with Alzheimer’s disease with mild...

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trial

The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and efficacy of KDS2010 in approximately 75 overweight or...

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neuro

The joint venture, Scilex Bio (“Scilex Bio JV”), will have global development and commercialization rights for a Phase 2 clinical stage, potential best-in-class novel oral tablet, KDS2010, for the...

Scilex Holding Company Announces Receipt of Notice from Nasdaq

PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing...

Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account (the...

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously

As previously announced, Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA, the “SPAC”) entered into...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.1308-20.43750.640.670.4822366060.55075165CS
4-0.1314-20.51201998130.64060.7450.455917975250.57948996CS
12-0.291-36.36590852290.80021.130.455921773070.81187272CS
26-1.2008-70.22222222221.712.30.455916426121.09250382CS
52-0.8508-62.55882352941.362.630.455912985431.20579953CS
156-9.5408-94.933333333310.0516.70.45599380472.56234952CS
260-9.5408-94.933333333310.0516.70.45599380472.56234952CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NUKKNukkleus Inc
US$ 11,655
(738,49%)
174,06M
PRTGPortage Biotech Inc
US$ 8,8678
(172,86%)
36,23M
OPTXSyntec Optics Holdings Inc
US$ 3,55
(99,44%)
92,44M
PTPIPetros Pharmaceuticals Inc
US$ 0,4976
(86,37%)
63,36M
LUXHLuxUrban Hotels Inc
US$ 0,849899
(59,67%)
29,51M
VCNXVaccinex Inc
US$ 1,41
(-61,37%)
758,95k
TNYATenaya Therapeutics Inc
US$ 1,395
(-51,56%)
42,45M
ORKTOrangeKloud Technology Inc
US$ 2,14
(-41,85%)
2,29M
RVPHReviva Pharmaceuticals Holdings Inc
US$ 1,395
(-39,35%)
18,16M
DBGIDigital Brands Group Inc
US$ 2,46
(-37,88%)
805,23k
RIMEAlgorhythm Holdings Inc
US$ 0,0877
(8,27%)
1,13B
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,335
(-36,79%)
1,02B
GOEVCanoo Inc
US$ 0,118
(7,08%)
388,43M
NVDANVIDIA Corporation
US$ 130,39
(-1,22%)
259,4M
XTIAXTI Aerospace Inc
US$ 0,0442
(8,33%)
222,55M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées